| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Interferon-alpha | 43 | 2014 | 921 | 2.620 |
Why?
|
| Antiviral Agents | 53 | 2021 | 3060 | 2.580 |
Why?
|
| Hepatitis B, Chronic | 22 | 2010 | 410 | 2.450 |
Why?
|
| Hepatitis C, Chronic | 42 | 2021 | 1032 | 2.350 |
Why?
|
| Hepatitis B virus | 39 | 2009 | 528 | 1.800 |
Why?
|
| Hepatitis C | 48 | 2021 | 1584 | 1.660 |
Why?
|
| Polyethylene Glycols | 27 | 2014 | 1189 | 1.620 |
Why?
|
| Hepatitis B | 55 | 2010 | 705 | 1.470 |
Why?
|
| Ribavirin | 22 | 2014 | 395 | 1.410 |
Why?
|
| Schools, Medical | 9 | 2022 | 879 | 1.390 |
Why?
|
| Hepatitis A | 45 | 2008 | 128 | 1.390 |
Why?
|
| Hepatitis, Viral, Human | 32 | 1999 | 141 | 1.350 |
Why?
|
| Lamivudine | 18 | 2007 | 366 | 1.290 |
Why?
|
| Liver Cirrhosis | 37 | 2017 | 1935 | 1.080 |
Why?
|
| Hepatitis B Surface Antigens | 38 | 2010 | 294 | 0.970 |
Why?
|
| Viral Hepatitis Vaccines | 14 | 2008 | 72 | 0.970 |
Why?
|
| Hepatitis B e Antigens | 17 | 2010 | 133 | 0.890 |
Why?
|
| Career Choice | 3 | 2020 | 756 | 0.850 |
Why?
|
| Nucleosides | 3 | 2009 | 131 | 0.850 |
Why?
|
| Reverse Transcriptase Inhibitors | 10 | 2003 | 621 | 0.840 |
Why?
|
| Liver Diseases, Alcoholic | 6 | 2020 | 156 | 0.820 |
Why?
|
| Education, Medical, Undergraduate | 6 | 2022 | 1070 | 0.820 |
Why?
|
| Hepatitis, Alcoholic | 4 | 2019 | 109 | 0.810 |
Why?
|
| Liver Transplantation | 17 | 2019 | 2330 | 0.810 |
Why?
|
| Behavioral Sciences | 2 | 2012 | 29 | 0.810 |
Why?
|
| Hepacivirus | 23 | 2021 | 1336 | 0.780 |
Why?
|
| School Admission Criteria | 3 | 2012 | 107 | 0.760 |
Why?
|
| Hepatovirus | 36 | 2000 | 45 | 0.660 |
Why?
|
| Liver | 38 | 2020 | 7529 | 0.650 |
Why?
|
| Hepatitis A Vaccines | 3 | 2008 | 26 | 0.600 |
Why?
|
| Alanine Transaminase | 29 | 2009 | 603 | 0.590 |
Why?
|
| Curriculum | 6 | 2022 | 3743 | 0.570 |
Why?
|
| Students, Medical | 5 | 2022 | 1936 | 0.560 |
Why?
|
| Educational Measurement | 3 | 2020 | 1255 | 0.560 |
Why?
|
| Education, Medical | 4 | 2016 | 1725 | 0.550 |
Why?
|
| Carcinoma, Hepatocellular | 13 | 2018 | 2297 | 0.550 |
Why?
|
| Social Dominance | 2 | 2013 | 39 | 0.540 |
Why?
|
| Recombinant Proteins | 41 | 2014 | 6534 | 0.520 |
Why?
|
| Job Satisfaction | 1 | 2020 | 544 | 0.520 |
Why?
|
| Achievement | 1 | 2017 | 288 | 0.500 |
Why?
|
| Organizational Culture | 3 | 2013 | 508 | 0.480 |
Why?
|
| College Admission Test | 2 | 2011 | 11 | 0.480 |
Why?
|
| Gastroenterology | 1 | 2021 | 577 | 0.470 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2014 | 25 | 0.460 |
Why?
|
| Liver Neoplasms | 15 | 2018 | 4319 | 0.440 |
Why?
|
| Problem-Based Learning | 2 | 2020 | 356 | 0.420 |
Why?
|
| Interprofessional Relations | 3 | 2013 | 990 | 0.410 |
Why?
|
| Minority Groups | 1 | 2020 | 1203 | 0.410 |
Why?
|
| Aggression | 2 | 2013 | 750 | 0.380 |
Why?
|
| Physicians | 5 | 2020 | 4591 | 0.370 |
Why?
|
| Clinical Competence | 8 | 2022 | 4793 | 0.360 |
Why?
|
| Guanine | 3 | 2007 | 279 | 0.360 |
Why?
|
| Vaccines, Synthetic | 3 | 2008 | 616 | 0.360 |
Why?
|
| Hepatitis B Vaccines | 14 | 1995 | 178 | 0.350 |
Why?
|
| Societies, Medical | 2 | 2021 | 3905 | 0.350 |
Why?
|
| Alcoholism | 4 | 2018 | 1973 | 0.330 |
Why?
|
| RNA, Viral | 14 | 2010 | 2846 | 0.320 |
Why?
|
| Education, Premedical | 1 | 2008 | 17 | 0.310 |
Why?
|
| Drug Therapy, Combination | 19 | 2014 | 6312 | 0.300 |
Why?
|
| Hepatitis B Antibodies | 17 | 2002 | 155 | 0.290 |
Why?
|
| Guidelines as Topic | 1 | 2014 | 1386 | 0.290 |
Why?
|
| Antigens, Viral | 21 | 1992 | 988 | 0.290 |
Why?
|
| Humans | 257 | 2022 | 761572 | 0.290 |
Why?
|
| Competency-Based Education | 1 | 2009 | 222 | 0.290 |
Why?
|
| Physician-Patient Relations | 3 | 2019 | 3249 | 0.270 |
Why?
|
| Hepatitis Viruses | 6 | 1990 | 15 | 0.260 |
Why?
|
| Hepatitis, Chronic | 5 | 1999 | 52 | 0.260 |
Why?
|
| Disease Progression | 21 | 2017 | 13510 | 0.260 |
Why?
|
| DNA, Viral | 13 | 2007 | 2202 | 0.250 |
Why?
|
| alpha-Fetoproteins | 4 | 2011 | 223 | 0.240 |
Why?
|
| End Stage Liver Disease | 2 | 2019 | 352 | 0.240 |
Why?
|
| Teaching | 2 | 2020 | 1170 | 0.240 |
Why?
|
| Hepatitis | 9 | 1996 | 228 | 0.240 |
Why?
|
| Pyrimidinones | 1 | 2007 | 385 | 0.230 |
Why?
|
| Disease Outbreaks | 11 | 2005 | 1749 | 0.230 |
Why?
|
| Viral Vaccines | 8 | 1985 | 596 | 0.230 |
Why?
|
| Blood Donors | 7 | 1991 | 345 | 0.230 |
Why?
|
| Data Interpretation, Statistical | 1 | 2014 | 2691 | 0.230 |
Why?
|
| Biopsy | 17 | 2018 | 6766 | 0.230 |
Why?
|
| Hepatitis B Antigens | 12 | 1986 | 38 | 0.220 |
Why?
|
| Guideline Adherence | 1 | 2014 | 2220 | 0.220 |
Why?
|
| Liver Diseases | 8 | 2021 | 1298 | 0.220 |
Why?
|
| Protein Precursors | 3 | 2011 | 1132 | 0.220 |
Why?
|
| History, 20th Century | 4 | 2021 | 2767 | 0.220 |
Why?
|
| Periodicals as Topic | 1 | 2014 | 1463 | 0.210 |
Why?
|
| Hospitals | 2 | 2013 | 3882 | 0.210 |
Why?
|
| Pan troglodytes | 19 | 1990 | 223 | 0.210 |
Why?
|
| Antibodies, Viral | 33 | 1994 | 3156 | 0.200 |
Why?
|
| Drug Carriers | 2 | 2006 | 706 | 0.200 |
Why?
|
| Male | 124 | 2021 | 360842 | 0.190 |
Why?
|
| Nobel Prize | 1 | 2021 | 48 | 0.190 |
Why?
|
| History, 21st Century | 2 | 2021 | 1567 | 0.190 |
Why?
|
| Clinical Clerkship | 2 | 2022 | 564 | 0.190 |
Why?
|
| Interferons | 5 | 2002 | 706 | 0.180 |
Why?
|
| Personnel, Hospital | 4 | 1992 | 285 | 0.180 |
Why?
|
| Biomedical Research | 1 | 2016 | 3429 | 0.180 |
Why?
|
| Female | 118 | 2020 | 392686 | 0.180 |
Why?
|
| Immunosuppressive Agents | 3 | 2012 | 4176 | 0.170 |
Why?
|
| Middle Aged | 92 | 2020 | 220920 | 0.170 |
Why?
|
| United States | 29 | 2021 | 72335 | 0.170 |
Why?
|
| Patient Care Management | 2 | 2017 | 302 | 0.170 |
Why?
|
| Interferon Regulatory Factor-3 | 1 | 2020 | 141 | 0.160 |
Why?
|
| Waiting Lists | 5 | 2019 | 765 | 0.160 |
Why?
|
| Maternal-Fetal Exchange | 4 | 1997 | 461 | 0.160 |
Why?
|
| Adult | 99 | 2020 | 221203 | 0.160 |
Why?
|
| Gap Junctions | 1 | 2020 | 230 | 0.160 |
Why?
|
| Antigen-Antibody Complex | 9 | 1983 | 510 | 0.150 |
Why?
|
| Research Design | 1 | 2014 | 6180 | 0.150 |
Why?
|
| Nucleotidyltransferases | 1 | 2020 | 244 | 0.150 |
Why?
|
| Occupational Diseases | 6 | 1989 | 1490 | 0.150 |
Why?
|
| Thinking | 1 | 2020 | 320 | 0.140 |
Why?
|
| Time Factors | 27 | 2019 | 39970 | 0.140 |
Why?
|
| Hepatorenal Syndrome | 1 | 2017 | 76 | 0.140 |
Why?
|
| Histocytochemistry | 1 | 2018 | 698 | 0.140 |
Why?
|
| Recurrence | 9 | 2018 | 8466 | 0.140 |
Why?
|
| Complementary Therapies | 1 | 2000 | 486 | 0.140 |
Why?
|
| Administration, Oral | 4 | 2009 | 4021 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 3713 | 0.130 |
Why?
|
| Hepatitis Antibodies | 7 | 1992 | 67 | 0.130 |
Why?
|
| Zalcitabine | 1 | 1995 | 43 | 0.130 |
Why?
|
| Treatment Outcome | 24 | 2017 | 64684 | 0.130 |
Why?
|
| Radiography, Abdominal | 1 | 2018 | 534 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 571 | 0.120 |
Why?
|
| Chronic Disease | 19 | 2001 | 9319 | 0.120 |
Why?
|
| Renal Dialysis | 7 | 2017 | 1796 | 0.120 |
Why?
|
| Liver Cirrhosis, Biliary | 4 | 1982 | 108 | 0.110 |
Why?
|
| Attitude | 1 | 2019 | 775 | 0.110 |
Why?
|
| Palliative Care | 2 | 2019 | 3598 | 0.110 |
Why?
|
| Callitrichinae | 8 | 1983 | 20 | 0.110 |
Why?
|
| Aspartate Aminotransferases | 9 | 2009 | 416 | 0.110 |
Why?
|
| Serologic Tests | 6 | 2010 | 381 | 0.110 |
Why?
|
| Immunization, Passive | 4 | 1989 | 616 | 0.110 |
Why?
|
| Massachusetts | 5 | 2017 | 8830 | 0.100 |
Why?
|
| Exons | 1 | 2018 | 2391 | 0.100 |
Why?
|
| Anemia, Aplastic | 2 | 1993 | 230 | 0.100 |
Why?
|
| Health Facility Administration | 1 | 2012 | 29 | 0.100 |
Why?
|
| Sexually Transmitted Diseases | 2 | 1997 | 662 | 0.100 |
Why?
|
| Lectins | 2 | 2011 | 491 | 0.100 |
Why?
|
| Adipokines | 2 | 2011 | 310 | 0.100 |
Why?
|
| Virus Replication | 4 | 2008 | 2435 | 0.100 |
Why?
|
| Ethanol | 1 | 2018 | 1324 | 0.100 |
Why?
|
| Advance Care Planning | 1 | 2019 | 699 | 0.100 |
Why?
|
| Platelet Count | 3 | 2009 | 781 | 0.090 |
Why?
|
| Clinical Enzyme Tests | 3 | 1987 | 113 | 0.090 |
Why?
|
| Hepatitis B Core Antigens | 10 | 1992 | 90 | 0.090 |
Why?
|
| Genotype | 11 | 2011 | 12990 | 0.090 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 2 | 2009 | 250 | 0.090 |
Why?
|
| Peer Review, Research | 1 | 2014 | 340 | 0.090 |
Why?
|
| Patient Selection | 4 | 2017 | 4244 | 0.090 |
Why?
|
| Immune Adherence Reaction | 10 | 1977 | 29 | 0.090 |
Why?
|
| Glomerulonephritis | 4 | 2006 | 331 | 0.090 |
Why?
|
| Commerce | 1 | 2016 | 606 | 0.090 |
Why?
|
| Transplantation Immunology | 1 | 2012 | 532 | 0.090 |
Why?
|
| Viremia | 3 | 1999 | 707 | 0.090 |
Why?
|
| Cholestasis, Intrahepatic | 2 | 2002 | 75 | 0.090 |
Why?
|
| Prospective Studies | 21 | 2022 | 54426 | 0.090 |
Why?
|
| Organizational Policy | 1 | 2012 | 432 | 0.090 |
Why?
|
| Immunoglobulins | 3 | 1989 | 852 | 0.080 |
Why?
|
| Retreatment | 2 | 2003 | 598 | 0.080 |
Why?
|
| Adenine | 2 | 2007 | 987 | 0.080 |
Why?
|
| Safety | 3 | 2003 | 1150 | 0.080 |
Why?
|
| Remedial Teaching | 1 | 2009 | 16 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2010 | 10212 | 0.080 |
Why?
|
| Lymphocytes | 5 | 1982 | 2612 | 0.080 |
Why?
|
| Chemistry | 2 | 2008 | 347 | 0.080 |
Why?
|
| Predictive Value of Tests | 6 | 2019 | 15266 | 0.080 |
Why?
|
| Feces | 10 | 1980 | 1497 | 0.080 |
Why?
|
| Hepatitis A Virus, Human | 1 | 2008 | 1 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 5 | 2008 | 6075 | 0.080 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2009 | 110 | 0.080 |
Why?
|
| Point Mutation | 1 | 1994 | 1595 | 0.080 |
Why?
|
| Drug Resistance, Microbial | 2 | 2003 | 825 | 0.080 |
Why?
|
| Professional Competence | 1 | 2011 | 431 | 0.080 |
Why?
|
| Faculty, Medical | 2 | 2020 | 1204 | 0.080 |
Why?
|
| Models, Educational | 1 | 2011 | 373 | 0.070 |
Why?
|
| Herbal Medicine | 1 | 2008 | 36 | 0.070 |
Why?
|
| Antibody Diversity | 1 | 1987 | 72 | 0.070 |
Why?
|
| Interferon Type I | 4 | 1994 | 562 | 0.070 |
Why?
|
| Altruism | 1 | 2009 | 208 | 0.070 |
Why?
|
| Forecasting | 1 | 2017 | 2928 | 0.070 |
Why?
|
| Blood Banks | 1 | 1988 | 108 | 0.070 |
Why?
|
| Drug Resistance, Viral | 3 | 2008 | 862 | 0.070 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2008 | 151 | 0.070 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 1998 | 1351 | 0.070 |
Why?
|
| Drug Administration Schedule | 6 | 2010 | 4853 | 0.070 |
Why?
|
| Radioimmunoassay | 8 | 1991 | 861 | 0.070 |
Why?
|
| Piperidines | 1 | 1996 | 1656 | 0.070 |
Why?
|
| Leukopenia | 1 | 2008 | 213 | 0.070 |
Why?
|
| Leucine | 2 | 1978 | 548 | 0.070 |
Why?
|
| Thymidine | 1 | 2007 | 299 | 0.070 |
Why?
|
| Professional-Patient Relations | 1 | 2012 | 726 | 0.070 |
Why?
|
| Quality of Life | 4 | 2021 | 13367 | 0.070 |
Why?
|
| Carrier State | 5 | 1985 | 523 | 0.070 |
Why?
|
| Risk Factors | 14 | 2019 | 74213 | 0.070 |
Why?
|
| Survival Rate | 6 | 2018 | 12725 | 0.070 |
Why?
|
| Cryoglobulins | 4 | 1981 | 58 | 0.070 |
Why?
|
| Biopsy, Needle | 2 | 2010 | 1626 | 0.070 |
Why?
|
| DNA, Circular | 1 | 2007 | 97 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2000 | 3205 | 0.070 |
Why?
|
| Haplorhini | 10 | 1980 | 525 | 0.070 |
Why?
|
| Vaccination | 5 | 1989 | 3384 | 0.070 |
Why?
|
| Biology | 1 | 2008 | 290 | 0.070 |
Why?
|
| Onions | 1 | 2005 | 6 | 0.070 |
Why?
|
| Cooperative Behavior | 2 | 2012 | 1505 | 0.060 |
Why?
|
| Information Dissemination | 1 | 2014 | 1126 | 0.060 |
Why?
|
| Prognosis | 10 | 2019 | 29629 | 0.060 |
Why?
|
| Social Behavior | 1 | 2012 | 1135 | 0.060 |
Why?
|
| Deltaretrovirus | 1 | 1985 | 162 | 0.060 |
Why?
|
| Universities | 2 | 2008 | 993 | 0.060 |
Why?
|
| Foodborne Diseases | 1 | 2005 | 41 | 0.060 |
Why?
|
| Kidney Transplantation | 7 | 1998 | 4235 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2011 | 823 | 0.060 |
Why?
|
| Defective Viruses | 1 | 1985 | 89 | 0.060 |
Why?
|
| Rubella | 1 | 1985 | 55 | 0.060 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 1924 | 0.060 |
Why?
|
| Fatty Liver | 2 | 2009 | 790 | 0.060 |
Why?
|
| Coffee | 1 | 2009 | 593 | 0.060 |
Why?
|
| Empathy | 1 | 2009 | 473 | 0.060 |
Why?
|
| Viral Load | 6 | 2010 | 3332 | 0.060 |
Why?
|
| Hyaluronic Acid | 1 | 2008 | 483 | 0.060 |
Why?
|
| Hepatitis A Antibodies | 3 | 1992 | 19 | 0.060 |
Why?
|
| Epitopes | 4 | 1992 | 2503 | 0.060 |
Why?
|
| Mass Screening | 4 | 2010 | 5428 | 0.060 |
Why?
|
| Hepatitis C Antibodies | 2 | 2001 | 146 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2007 | 629 | 0.060 |
Why?
|
| Agriculture | 1 | 2005 | 191 | 0.060 |
Why?
|
| Hemophilia A | 4 | 1990 | 360 | 0.060 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2010 | 1039 | 0.060 |
Why?
|
| Gene Amplification | 1 | 2008 | 1089 | 0.060 |
Why?
|
| Hepatitis, Viral, Animal | 3 | 1980 | 10 | 0.060 |
Why?
|
| Microscopy, Electron | 9 | 1983 | 2561 | 0.060 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 1516 | 0.060 |
Why?
|
| Severity of Illness Index | 6 | 2019 | 15843 | 0.060 |
Why?
|
| Thrombocytopenia | 2 | 2010 | 1182 | 0.050 |
Why?
|
| Jaundice | 2 | 1985 | 94 | 0.050 |
Why?
|
| Retrospective Studies | 16 | 2021 | 80646 | 0.050 |
Why?
|
| Mutation | 7 | 2018 | 30054 | 0.050 |
Why?
|
| Collagen | 2 | 2009 | 2638 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2012 | 6484 | 0.050 |
Why?
|
| Organophosphorus Compounds | 1 | 2004 | 206 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2007 | 857 | 0.050 |
Why?
|
| Sexual Behavior | 2 | 2010 | 2180 | 0.050 |
Why?
|
| Learning | 2 | 2022 | 1740 | 0.050 |
Why?
|
| Aged | 35 | 2018 | 169310 | 0.050 |
Why?
|
| Viral Nonstructural Proteins | 3 | 1999 | 227 | 0.050 |
Why?
|
| Cytomegalovirus | 5 | 1983 | 756 | 0.050 |
Why?
|
| Interpersonal Relations | 1 | 2009 | 1436 | 0.050 |
Why?
|
| Paraproteinemias | 3 | 1981 | 248 | 0.050 |
Why?
|
| Immune Complex Diseases | 2 | 1981 | 50 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 5 | 2005 | 5492 | 0.050 |
Why?
|
| Liver Function Tests | 5 | 2008 | 523 | 0.050 |
Why?
|
| Terminology as Topic | 2 | 2001 | 1530 | 0.050 |
Why?
|
| Age of Onset | 1 | 2008 | 3306 | 0.050 |
Why?
|
| Gene Products, pol | 1 | 2001 | 43 | 0.050 |
Why?
|
| Necrosis | 2 | 2003 | 1611 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 4243 | 0.050 |
Why?
|
| Antilymphocyte Serum | 2 | 1982 | 487 | 0.050 |
Why?
|
| Internship and Residency | 2 | 2020 | 5882 | 0.050 |
Why?
|
| Adolescent | 28 | 2006 | 88324 | 0.040 |
Why?
|
| Operating Room Technicians | 1 | 1980 | 15 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2006 | 909 | 0.040 |
Why?
|
| Halothane | 1 | 1980 | 200 | 0.040 |
Why?
|
| Prothrombin | 2 | 2011 | 191 | 0.040 |
Why?
|
| Immunoglobulin M | 7 | 1985 | 1526 | 0.040 |
Why?
|
| Proportional Hazards Models | 6 | 2012 | 12463 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 5315 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 1996 | 3808 | 0.040 |
Why?
|
| Food Handling | 3 | 1981 | 154 | 0.040 |
Why?
|
| Immune Tolerance | 1 | 2008 | 2302 | 0.040 |
Why?
|
| DNA-Directed DNA Polymerase | 4 | 2001 | 489 | 0.040 |
Why?
|
| Hemagglutination Tests | 6 | 1977 | 76 | 0.040 |
Why?
|
| Viral Proteins | 1 | 1986 | 1804 | 0.040 |
Why?
|
| Drug Approval | 1 | 2006 | 814 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 1998 | 1784 | 0.040 |
Why?
|
| Vitamin D | 1 | 2012 | 3303 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2010 | 3424 | 0.040 |
Why?
|
| Genetic Variation | 3 | 2003 | 6567 | 0.040 |
Why?
|
| Bilirubin | 5 | 2009 | 436 | 0.040 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 1 | 1997 | 29 | 0.040 |
Why?
|
| Follow-Up Studies | 8 | 2018 | 39107 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 3 | 2017 | 7391 | 0.040 |
Why?
|
| Prevalence | 6 | 2011 | 15732 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 12148 | 0.040 |
Why?
|
| Japan | 4 | 1994 | 1378 | 0.040 |
Why?
|
| Antibody Formation | 6 | 1989 | 1395 | 0.030 |
Why?
|
| Urticaria | 1 | 1978 | 150 | 0.030 |
Why?
|
| Double-Blind Method | 4 | 1999 | 12341 | 0.030 |
Why?
|
| Treatment Failure | 3 | 2009 | 2644 | 0.030 |
Why?
|
| Bivalvia | 1 | 1976 | 55 | 0.030 |
Why?
|
| Hepatitis delta Antigens | 3 | 1985 | 7 | 0.030 |
Why?
|
| Weight Loss | 1 | 2008 | 2684 | 0.030 |
Why?
|
| B-Lymphocytes | 2 | 1987 | 4758 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 20571 | 0.030 |
Why?
|
| Incidence | 6 | 2011 | 21355 | 0.030 |
Why?
|
| Cultural Competency | 1 | 2019 | 300 | 0.030 |
Why?
|
| Health Personnel | 1 | 2009 | 3335 | 0.030 |
Why?
|
| Logistic Models | 4 | 2012 | 13255 | 0.030 |
Why?
|
| Antigen-Antibody Reactions | 4 | 1976 | 340 | 0.030 |
Why?
|
| Animals | 32 | 2020 | 168467 | 0.030 |
Why?
|
| Enterovirus B, Human | 1 | 1975 | 47 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 4 | 1985 | 2468 | 0.030 |
Why?
|
| Sexually Transmitted Diseases, Viral | 1 | 1995 | 40 | 0.030 |
Why?
|
| Procollagen | 2 | 2008 | 187 | 0.030 |
Why?
|
| Hepatic Encephalopathy | 3 | 1987 | 144 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 7593 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2020 | 1139 | 0.030 |
Why?
|
| Socioeconomic Factors | 5 | 2016 | 7827 | 0.030 |
Why?
|
| Fibrosis | 2 | 2012 | 2049 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2001 | 1468 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 13382 | 0.030 |
Why?
|
| Postoperative Complications | 5 | 1999 | 15633 | 0.030 |
Why?
|
| Lipoproteins | 1 | 1978 | 881 | 0.030 |
Why?
|
| Blood Transfusion | 3 | 1995 | 1301 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2006 | 2472 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2020 | 1233 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 1996 | 13642 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2011 | 17904 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 1999 | 1264 | 0.030 |
Why?
|
| Concanavalin A | 3 | 1982 | 190 | 0.030 |
Why?
|
| Hierarchy, Social | 1 | 2012 | 24 | 0.030 |
Why?
|
| Family Health | 1 | 1997 | 1257 | 0.030 |
Why?
|
| Risk | 6 | 1987 | 9610 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 5 | 1983 | 1078 | 0.030 |
Why?
|
| Codes of Ethics | 1 | 2012 | 61 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2012 | 14607 | 0.020 |
Why?
|
| Hepatitis Delta Virus | 2 | 1994 | 24 | 0.020 |
Why?
|
| Patient Admission | 1 | 2019 | 1367 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2001 | 2242 | 0.020 |
Why?
|
| Israel | 1 | 1994 | 726 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 15936 | 0.020 |
Why?
|
| Aminoglycosides | 1 | 1972 | 160 | 0.020 |
Why?
|
| Molecular Sequence Data | 4 | 2001 | 17635 | 0.020 |
Why?
|
| Malaria | 1 | 1981 | 1227 | 0.020 |
Why?
|
| Virus Cultivation | 2 | 1981 | 88 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 1992 | 397 | 0.020 |
Why?
|
| Risk Assessment | 4 | 2019 | 23996 | 0.020 |
Why?
|
| Immunoglobulin G | 7 | 1985 | 4544 | 0.020 |
Why?
|
| Survival Analysis | 3 | 2001 | 10090 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1994 | 1693 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 36429 | 0.020 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1995 | 529 | 0.020 |
Why?
|
| Health Status | 2 | 2017 | 4077 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 1994 | 1574 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2004 | 10766 | 0.020 |
Why?
|
| Blood-Borne Pathogens | 1 | 2009 | 52 | 0.020 |
Why?
|
| Resource Allocation | 1 | 1992 | 350 | 0.020 |
Why?
|
| Clinical Trials as Topic | 6 | 2008 | 8002 | 0.020 |
Why?
|
| Pilot Projects | 4 | 2009 | 8633 | 0.020 |
Why?
|
| Anesthesiology | 1 | 1980 | 1120 | 0.020 |
Why?
|
| DNA Primers | 1 | 1994 | 2819 | 0.020 |
Why?
|
| Needlestick Injuries | 1 | 2009 | 71 | 0.020 |
Why?
|
| Benzopyrenes | 1 | 1968 | 5 | 0.020 |
Why?
|
| Morals | 1 | 2012 | 289 | 0.020 |
Why?
|
| Benz(a)Anthracenes | 1 | 1968 | 11 | 0.020 |
Why?
|
| Methylcholanthrene | 1 | 1968 | 31 | 0.020 |
Why?
|
| Drinking Behavior | 1 | 2009 | 103 | 0.020 |
Why?
|
| Antibodies, Fungal | 1 | 1989 | 34 | 0.020 |
Why?
|
| Molecular Biology | 1 | 1993 | 576 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1993 | 664 | 0.020 |
Why?
|
| Cytodiagnosis | 1 | 1993 | 447 | 0.020 |
Why?
|
| HIV Infections | 2 | 2008 | 17352 | 0.020 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 58986 | 0.020 |
Why?
|
| Hepatitis, Animal | 2 | 1980 | 19 | 0.020 |
Why?
|
| Health Care Rationing | 1 | 1992 | 437 | 0.020 |
Why?
|
| Liver Cirrhosis, Alcoholic | 2 | 1978 | 64 | 0.020 |
Why?
|
| Personality | 1 | 2012 | 554 | 0.020 |
Why?
|
| Genes, MHC Class II | 1 | 1989 | 434 | 0.020 |
Why?
|
| Child | 20 | 1995 | 80156 | 0.020 |
Why?
|
| Drug Combinations | 2 | 2008 | 2048 | 0.020 |
Why?
|
| Immunoblotting | 1 | 1991 | 1646 | 0.020 |
Why?
|
| Disease Models, Animal | 5 | 1981 | 18253 | 0.020 |
Why?
|
| Health Surveys | 2 | 2009 | 4061 | 0.020 |
Why?
|
| Child, Preschool | 15 | 1995 | 42230 | 0.020 |
Why?
|
| Hospitals, General | 1 | 1992 | 798 | 0.020 |
Why?
|
| Silymarin | 1 | 2008 | 46 | 0.020 |
Why?
|
| Cohort Studies | 5 | 2018 | 41493 | 0.020 |
Why?
|
| Yeasts | 1 | 1989 | 279 | 0.020 |
Why?
|
| Cross Infection | 3 | 1986 | 1422 | 0.020 |
Why?
|
| Health Occupations | 1 | 1989 | 222 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 26127 | 0.020 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 1995 | 1351 | 0.020 |
Why?
|
| Ascites | 1 | 2009 | 338 | 0.020 |
Why?
|
| Complement Fixation Tests | 2 | 1977 | 68 | 0.020 |
Why?
|
| Acute Disease | 5 | 1983 | 7237 | 0.020 |
Why?
|
| Liver Failure | 1 | 2009 | 250 | 0.020 |
Why?
|
| Peritonitis | 1 | 2009 | 368 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 1993 | 831 | 0.020 |
Why?
|
| Rheumatoid Factor | 2 | 1985 | 185 | 0.020 |
Why?
|
| Multivariate Analysis | 3 | 2009 | 12059 | 0.020 |
Why?
|
| Transplantation, Homologous | 2 | 1994 | 4807 | 0.020 |
Why?
|
| Quality Improvement | 2 | 2012 | 3801 | 0.020 |
Why?
|
| Graft Survival | 3 | 1992 | 3820 | 0.020 |
Why?
|
| Europe | 1 | 1994 | 3422 | 0.020 |
Why?
|
| Food Contamination | 2 | 1979 | 191 | 0.020 |
Why?
|
| Antibody Affinity | 1 | 1987 | 246 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2011 | 1699 | 0.020 |
Why?
|
| Injections, Intradermal | 1 | 1986 | 116 | 0.020 |
Why?
|
| Hepatitis D | 1 | 1986 | 23 | 0.020 |
Why?
|
| Drug Resistance | 2 | 2004 | 1596 | 0.020 |
Why?
|
| Pregnancy | 4 | 1997 | 29876 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2009 | 672 | 0.020 |
Why?
|
| Immunization | 2 | 1981 | 1227 | 0.020 |
Why?
|
| Sick Role | 1 | 1987 | 229 | 0.020 |
Why?
|
| Algorithms | 1 | 2007 | 14032 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 3639 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2019 | 3600 | 0.020 |
Why?
|
| DNA Probes | 1 | 2007 | 541 | 0.020 |
Why?
|
| Chemical Precipitation | 1 | 1985 | 175 | 0.020 |
Why?
|
| Prednisone | 1 | 1990 | 1563 | 0.020 |
Why?
|
| Homosexuality | 2 | 1985 | 267 | 0.020 |
Why?
|
| Inclusion Bodies, Viral | 2 | 1975 | 45 | 0.020 |
Why?
|
| Computers | 1 | 2008 | 593 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 1968 | 730 | 0.020 |
Why?
|
| Psychophysiologic Disorders | 1 | 1987 | 221 | 0.020 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2006 | 189 | 0.020 |
Why?
|
| Attitude to Health | 1 | 1994 | 2025 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 3889 | 0.020 |
Why?
|
| Cyclosporins | 1 | 1985 | 216 | 0.020 |
Why?
|
| Hepatolenticular Degeneration | 1 | 1985 | 72 | 0.020 |
Why?
|
| Genes, Viral | 1 | 1986 | 649 | 0.020 |
Why?
|
| Food, Formulated | 1 | 1985 | 101 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2020 | 14416 | 0.010 |
Why?
|
| Communication | 1 | 2019 | 3873 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 1994 | 2421 | 0.010 |
Why?
|
| Organ Transplantation | 1 | 1995 | 1157 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 2 | 1984 | 1624 | 0.010 |
Why?
|
| Syndrome | 2 | 1981 | 3267 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2007 | 931 | 0.010 |
Why?
|
| Drug Contamination | 1 | 1985 | 152 | 0.010 |
Why?
|
| Counterimmunoelectrophoresis | 1 | 1983 | 14 | 0.010 |
Why?
|
| Apoptosis | 1 | 2020 | 9489 | 0.010 |
Why?
|
| Immunodiffusion | 1 | 1983 | 141 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2011 | 3606 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1985 | 641 | 0.010 |
Why?
|
| Thyroxine-Binding Proteins | 1 | 1983 | 24 | 0.010 |
Why?
|
| Registries | 1 | 2019 | 8224 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 5 | 1984 | 3080 | 0.010 |
Why?
|
| Rabbits | 2 | 1980 | 4772 | 0.010 |
Why?
|
| Comorbidity | 1 | 2017 | 10508 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2012 | 22176 | 0.010 |
Why?
|
| Canada | 1 | 1988 | 2122 | 0.010 |
Why?
|
| Leadership | 1 | 2012 | 1385 | 0.010 |
Why?
|
| Centrifugation, Isopycnic | 3 | 1976 | 8 | 0.010 |
Why?
|
| Base Sequence | 1 | 1994 | 12441 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2018 | 4652 | 0.010 |
Why?
|
| Urban Population | 3 | 1981 | 2036 | 0.010 |
Why?
|
| Fatigue | 1 | 2010 | 1552 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2004 | 615 | 0.010 |
Why?
|
| Australia | 2 | 1976 | 1250 | 0.010 |
Why?
|
| Complement System Proteins | 3 | 1986 | 735 | 0.010 |
Why?
|
| Life Style | 1 | 1994 | 3917 | 0.010 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 2735 | 0.010 |
Why?
|
| Transfer Factor | 1 | 1981 | 5 | 0.010 |
Why?
|
| Amino Acid Sequence | 3 | 2001 | 13446 | 0.010 |
Why?
|
| Boston | 3 | 1985 | 9326 | 0.010 |
Why?
|
| Population Surveillance | 1 | 1992 | 2598 | 0.010 |
Why?
|
| Collagen Type III | 1 | 2001 | 91 | 0.010 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2007 | 1118 | 0.010 |
Why?
|
| Prisoners | 2 | 1985 | 314 | 0.010 |
Why?
|
| Parenteral Nutrition, Total | 1 | 1982 | 304 | 0.010 |
Why?
|
| Age Factors | 7 | 1992 | 18398 | 0.010 |
Why?
|
| Mitogens | 1 | 1981 | 230 | 0.010 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 1981 | 111 | 0.010 |
Why?
|
| New York City | 3 | 1978 | 731 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 1978 | 7858 | 0.010 |
Why?
|
| Plasmodium malariae | 1 | 1981 | 13 | 0.010 |
Why?
|
| Antibodies, Neoplasm | 1 | 1982 | 281 | 0.010 |
Why?
|
| Serum Sickness | 1 | 1981 | 27 | 0.010 |
Why?
|
| Infant | 7 | 1995 | 36192 | 0.010 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 1981 | 42 | 0.010 |
Why?
|
| Naval Medicine | 2 | 1979 | 30 | 0.010 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1985 | 547 | 0.010 |
Why?
|
| Polymyalgia Rheumatica | 1 | 1981 | 52 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 6346 | 0.010 |
Why?
|
| Bacteria | 1 | 1972 | 2199 | 0.010 |
Why?
|
| Raynaud Disease | 1 | 1981 | 79 | 0.010 |
Why?
|
| Purpura | 1 | 1981 | 117 | 0.010 |
Why?
|
| Polyarteritis Nodosa | 1 | 1981 | 70 | 0.010 |
Why?
|
| Kidney Glomerulus | 1 | 1983 | 568 | 0.010 |
Why?
|
| Cause of Death | 1 | 2011 | 3683 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1983 | 1705 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2008 | 2696 | 0.010 |
Why?
|
| Human Experimentation | 1 | 1981 | 123 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 5790 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2008 | 2203 | 0.010 |
Why?
|
| DNA | 2 | 1977 | 7213 | 0.010 |
Why?
|
| Burkitt Lymphoma | 1 | 1982 | 335 | 0.010 |
Why?
|
| DNA Viruses | 1 | 1980 | 34 | 0.010 |
Why?
|
| Models, Biological | 3 | 1987 | 9469 | 0.010 |
Why?
|
| Flaviviridae | 1 | 1999 | 9 | 0.010 |
Why?
|
| Antigens, Surface | 2 | 1982 | 1606 | 0.010 |
Why?
|
| Antibody Specificity | 3 | 1992 | 1060 | 0.010 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 1982 | 269 | 0.010 |
Why?
|
| Random Allocation | 1 | 1984 | 2395 | 0.010 |
Why?
|
| Health Policy | 1 | 1992 | 2684 | 0.010 |
Why?
|
| Immunologic Techniques | 1 | 1980 | 212 | 0.010 |
Why?
|
| Thyroxine | 1 | 1983 | 666 | 0.010 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 1979 | 45 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 1999 | 3810 | 0.010 |
Why?
|
| Hyperbilirubinemia | 1 | 1979 | 74 | 0.010 |
Why?
|
| Carbon Tetrachloride Poisoning | 1 | 1978 | 11 | 0.010 |
Why?
|
| Dermatitis | 1 | 1981 | 202 | 0.010 |
Why?
|
| Occupational Exposure | 1 | 2009 | 1813 | 0.010 |
Why?
|
| Plasmodium vivax | 1 | 1981 | 202 | 0.010 |
Why?
|
| Muscles | 3 | 1982 | 1576 | 0.010 |
Why?
|
| RNA Viruses | 1 | 1980 | 111 | 0.010 |
Why?
|
| Substance-Related Disorders | 2 | 1986 | 4420 | 0.010 |
Why?
|
| Lymphotoxin-alpha | 1 | 1978 | 93 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1999 | 767 | 0.010 |
Why?
|
| Epidemiologic Methods | 2 | 1985 | 1336 | 0.010 |
Why?
|
| Mice | 3 | 2020 | 81533 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1978 | 321 | 0.010 |
Why?
|
| Antibodies | 2 | 1996 | 2418 | 0.010 |
Why?
|
| gamma-Glutamyltransferase | 1 | 1978 | 144 | 0.010 |
Why?
|
| Viral Structural Proteins | 1 | 1998 | 95 | 0.010 |
Why?
|
| Placebos | 1 | 2002 | 1667 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 14666 | 0.010 |
Why?
|
| Guinea Pigs | 2 | 1976 | 1310 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1993 | 12794 | 0.010 |
Why?
|
| Virion | 1 | 1980 | 422 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2001 | 926 | 0.010 |
Why?
|
| Parenteral Nutrition | 1 | 1982 | 659 | 0.010 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 1980 | 367 | 0.010 |
Why?
|
| Anaphylaxis | 1 | 1985 | 757 | 0.010 |
Why?
|
| ROC Curve | 1 | 2005 | 3579 | 0.010 |
Why?
|
| Thalassemia | 1 | 1978 | 267 | 0.010 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 1978 | 303 | 0.010 |
Why?
|
| Immunity, Cellular | 2 | 1980 | 1560 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2002 | 1835 | 0.010 |
Why?
|
| Joint Diseases | 1 | 1981 | 459 | 0.010 |
Why?
|
| Immune Sera | 1 | 1977 | 606 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2020 | 23447 | 0.010 |
Why?
|
| Animals, Zoo | 1 | 1976 | 15 | 0.010 |
Why?
|
| Vasculitis | 1 | 1981 | 521 | 0.010 |
Why?
|
| Biological Products | 1 | 1986 | 914 | 0.010 |
Why?
|
| Monkey Diseases | 1 | 1976 | 71 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1986 | 3396 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2009 | 5972 | 0.010 |
Why?
|
| Inositol | 1 | 1977 | 215 | 0.010 |
Why?
|
| Neoplasms | 1 | 1985 | 22173 | 0.010 |
Why?
|
| Phosphatidylinositols | 1 | 1977 | 282 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1996 | 372 | 0.010 |
Why?
|
| Cholestasis | 1 | 1979 | 378 | 0.010 |
Why?
|
| Body Weight | 1 | 2006 | 4618 | 0.010 |
Why?
|
| Immunoglobulin A | 2 | 1978 | 978 | 0.010 |
Why?
|
| T-Lymphocytes | 2 | 1984 | 10194 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2010 | 5079 | 0.010 |
Why?
|
| Arthritis | 1 | 1981 | 680 | 0.010 |
Why?
|
| Zoonoses | 1 | 1976 | 179 | 0.010 |
Why?
|
| Bile | 1 | 1976 | 298 | 0.010 |
Why?
|
| Water Microbiology | 1 | 1976 | 113 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2008 | 5112 | 0.010 |
Why?
|
| Phenotype | 2 | 2011 | 16592 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1999 | 2748 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 2 | 1990 | 1702 | 0.010 |
Why?
|
| Body Fluids | 1 | 1976 | 320 | 0.010 |
Why?
|
| Heart Arrest | 1 | 1985 | 1514 | 0.010 |
Why?
|
| Afghanistan | 2 | 1985 | 78 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2001 | 1475 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1976 | 817 | 0.010 |
Why?
|
| Serotyping | 1 | 1975 | 325 | 0.010 |
Why?
|
| Clone Cells | 1 | 1998 | 1659 | 0.010 |
Why?
|
| Actins | 1 | 2001 | 2050 | 0.010 |
Why?
|
| Transaminases | 2 | 1990 | 198 | 0.010 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 1998 | 828 | 0.010 |
Why?
|
| Germany | 1 | 1976 | 875 | 0.010 |
Why?
|
| Autoantigens | 1 | 1978 | 891 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 2 | 1976 | 299 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1986 | 4217 | 0.010 |
Why?
|
| Tritium | 2 | 1977 | 708 | 0.010 |
Why?
|
| Infusions, Parenteral | 2 | 1985 | 397 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 5841 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1972 | 7407 | 0.010 |
Why?
|
| Acyclovir | 1 | 1993 | 268 | 0.010 |
Why?
|
| Immunosorbents | 1 | 1992 | 21 | 0.010 |
Why?
|
| Genome | 1 | 2001 | 1740 | 0.010 |
Why?
|
| California | 1 | 1977 | 1430 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1981 | 1881 | 0.010 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 1992 | 162 | 0.010 |
Why?
|
| Tacrolimus | 1 | 1996 | 733 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 4575 | 0.010 |
Why?
|
| Obesity | 2 | 1991 | 12947 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2009 | 12954 | 0.010 |
Why?
|
| Skin | 3 | 1983 | 4484 | 0.010 |
Why?
|
| Autoantibodies | 1 | 1980 | 2116 | 0.010 |
Why?
|
| Drug Hypersensitivity | 1 | 1980 | 917 | 0.010 |
Why?
|
| General Surgery | 1 | 1982 | 1692 | 0.010 |
Why?
|
| Plasmodium falciparum | 1 | 1981 | 1742 | 0.010 |
Why?
|
| Diagnosis, Differential | 3 | 1983 | 12975 | 0.010 |
Why?
|
| Opportunistic Infections | 1 | 1993 | 376 | 0.010 |
Why?
|
| Health Planning | 1 | 1992 | 230 | 0.010 |
Why?
|
| Life Support Care | 1 | 1992 | 226 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1976 | 710 | 0.010 |
Why?
|
| Virus Diseases | 1 | 1976 | 718 | 0.010 |
Why?
|
| Medical Records | 1 | 1996 | 1408 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 20099 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2000 | 2690 | 0.010 |
Why?
|
| Federal Government | 1 | 1992 | 267 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 1982 | 3066 | 0.010 |
Why?
|
| Specimen Handling | 1 | 1975 | 702 | 0.010 |
Why?
|
| Antigens | 1 | 1975 | 1443 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 1995 | 15501 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1998 | 1974 | 0.010 |
Why?
|
| Culture Media | 1 | 1972 | 897 | 0.010 |
Why?
|
| Chromatography, Paper | 1 | 1968 | 76 | 0.010 |
Why?
|
| Young Adult | 1 | 2016 | 59255 | 0.010 |
Why?
|
| Pain | 1 | 1984 | 5073 | 0.010 |
Why?
|
| New England | 1 | 1992 | 1054 | 0.010 |
Why?
|
| Intraoperative Complications | 1 | 1995 | 1166 | 0.000 |
Why?
|
| Down Syndrome | 1 | 1977 | 901 | 0.000 |
Why?
|
| Chemical Phenomena | 1 | 1968 | 507 | 0.000 |
Why?
|
| Sequence Analysis, DNA | 1 | 1999 | 4740 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 11076 | 0.000 |
Why?
|
| Gene Expression Regulation | 1 | 1986 | 11904 | 0.000 |
Why?
|
| Mental Disorders | 1 | 1987 | 6845 | 0.000 |
Why?
|
| Drug Synergism | 1 | 1972 | 1756 | 0.000 |
Why?
|
| Deoxyribonucleases | 1 | 1968 | 211 | 0.000 |
Why?
|
| Italy | 1 | 1989 | 842 | 0.000 |
Why?
|
| Adjustment Disorders | 1 | 1987 | 67 | 0.000 |
Why?
|
| Major Histocompatibility Complex | 1 | 1989 | 870 | 0.000 |
Why?
|
| Cell Line | 1 | 1980 | 15601 | 0.000 |
Why?
|
| Haploidy | 1 | 1986 | 126 | 0.000 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1992 | 1349 | 0.000 |
Why?
|
| Factor VIII | 1 | 1988 | 348 | 0.000 |
Why?
|
| Alkaline Phosphatase | 1 | 1968 | 864 | 0.000 |
Why?
|
| Neomycin | 1 | 1985 | 92 | 0.000 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1972 | 1937 | 0.000 |
Why?
|
| Immunization Schedule | 1 | 1986 | 227 | 0.000 |
Why?
|
| Ceruloplasmin | 1 | 1985 | 56 | 0.000 |
Why?
|
| Rats | 2 | 1978 | 23741 | 0.000 |
Why?
|
| Analysis of Variance | 1 | 1993 | 6228 | 0.000 |
Why?
|
| HLA-DR Antigens | 1 | 1986 | 602 | 0.000 |
Why?
|
| HIV Seropositivity | 1 | 1990 | 960 | 0.000 |
Why?
|
| Homozygote | 1 | 1989 | 1776 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1985 | 26198 | 0.000 |
Why?
|
| Genetic Linkage | 1 | 1989 | 2341 | 0.000 |
Why?
|
| Tissue and Organ Procurement | 1 | 1992 | 962 | 0.000 |
Why?
|
| 2-Hydroxyphenethylamine | 1 | 1982 | 2 | 0.000 |
Why?
|
| Immunization, Secondary | 1 | 1985 | 367 | 0.000 |
Why?
|
| Hospitals, State | 1 | 1982 | 28 | 0.000 |
Why?
|
| Heterozygote | 1 | 1989 | 2787 | 0.000 |
Why?
|
| Copper | 1 | 1985 | 369 | 0.000 |
Why?
|
| Thyroid Function Tests | 1 | 1983 | 288 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1998 | 18965 | 0.000 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1986 | 1435 | 0.000 |
Why?
|
| Blotting, Western | 1 | 1989 | 5035 | 0.000 |
Why?
|
| Pokeweed Mitogens | 1 | 1981 | 38 | 0.000 |
Why?
|
| Skin Manifestations | 1 | 1981 | 17 | 0.000 |
Why?
|
| Reoperation | 1 | 1992 | 4303 | 0.000 |
Why?
|
| Toxoplasma | 1 | 1983 | 157 | 0.000 |
Why?
|
| Ammonia | 1 | 1982 | 237 | 0.000 |
Why?
|
| Triiodothyronine | 1 | 1983 | 493 | 0.000 |
Why?
|
| Physical Examination | 1 | 1987 | 1255 | 0.000 |
Why?
|
| HLA Antigens | 1 | 1986 | 1328 | 0.000 |
Why?
|
| Hyperthyroidism | 1 | 1983 | 294 | 0.000 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1989 | 3733 | 0.000 |
Why?
|
| Thyroid Hormones | 1 | 1983 | 404 | 0.000 |
Why?
|
| Atrophy | 1 | 1985 | 1633 | 0.000 |
Why?
|
| Rosette Formation | 1 | 1979 | 152 | 0.000 |
Why?
|
| Dietary Proteins | 1 | 1985 | 952 | 0.000 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1984 | 974 | 0.000 |
Why?
|
| London | 1 | 1979 | 234 | 0.000 |
Why?
|
| Lymphocyte Activation | 2 | 1981 | 5485 | 0.000 |
Why?
|
| Immunologic Memory | 1 | 1985 | 1359 | 0.000 |
Why?
|
| Hospital Units | 1 | 1979 | 142 | 0.000 |
Why?
|
| Brazil | 1 | 1982 | 1230 | 0.000 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 1978 | 109 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1982 | 1596 | 0.000 |
Why?
|
| Cerebellum | 1 | 1985 | 1501 | 0.000 |
Why?
|
| Psychotherapy | 1 | 1987 | 1647 | 0.000 |
Why?
|
| Complement C4 | 1 | 1978 | 217 | 0.000 |
Why?
|
| Senegal | 1 | 1977 | 256 | 0.000 |
Why?
|
| Commitment of Mentally Ill | 1 | 1977 | 94 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 2 | 1985 | 9177 | 0.000 |
Why?
|
| Cesium | 1 | 1976 | 36 | 0.000 |
Why?
|
| Mitochondria, Liver | 1 | 1977 | 190 | 0.000 |
Why?
|
| Amino Acids | 1 | 1982 | 1718 | 0.000 |
Why?
|
| Length of Stay | 2 | 1982 | 6426 | 0.000 |
Why?
|
| Synaptic Transmission | 1 | 1982 | 1173 | 0.000 |
Why?
|
| Electrophoresis | 1 | 1976 | 227 | 0.000 |
Why?
|
| Complement C3 | 1 | 1978 | 435 | 0.000 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1984 | 2199 | 0.000 |
Why?
|
| Convalescence | 1 | 1976 | 105 | 0.000 |
Why?
|
| Food Microbiology | 1 | 1975 | 74 | 0.000 |
Why?
|
| Binding, Competitive | 1 | 1976 | 1141 | 0.000 |
Why?
|
| Alcohol Drinking | 1 | 1987 | 4028 | 0.000 |
Why?
|
| Platelet Transfusion | 1 | 1977 | 298 | 0.000 |
Why?
|
| Medicare | 1 | 1992 | 6770 | 0.000 |
Why?
|
| Emigration and Immigration | 1 | 1976 | 397 | 0.000 |
Why?
|
| Education | 1 | 1976 | 537 | 0.000 |
Why?
|
| Glucose | 1 | 1985 | 4346 | 0.000 |
Why?
|
| Tendons | 1 | 1977 | 558 | 0.000 |
Why?
|
| Muscular Diseases | 1 | 1976 | 553 | 0.000 |
Why?
|
| Lysosomes | 1 | 1977 | 924 | 0.000 |
Why?
|
| Lymph Nodes | 1 | 1983 | 3466 | 0.000 |
Why?
|
| Endoplasmic Reticulum | 1 | 1977 | 1134 | 0.000 |
Why?
|
| Adaptation, Physiological | 1 | 1977 | 1301 | 0.000 |
Why?
|
| Bone Marrow Cells | 1 | 1977 | 2417 | 0.000 |
Why?
|
| Bone Marrow Transplantation | 1 | 1977 | 2693 | 0.000 |
Why?
|
| Cell Nucleus | 1 | 1977 | 2910 | 0.000 |
Why?
|
| Residence Characteristics | 1 | 1977 | 2094 | 0.000 |
Why?
|
| Social Class | 1 | 1976 | 2004 | 0.000 |
Why?
|
| Cell Membrane | 1 | 1977 | 3687 | 0.000 |
Why?
|
| RNA | 1 | 1977 | 2726 | 0.000 |
Why?
|